Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action
Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established....
Saved in:
Sonstige: | |
---|---|
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (206 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993562964604498 |
---|---|
ctrlnum |
(CKB)5670000000391619 (oapen)https://directory.doabooks.org/handle/20.500.12854/93214 (EXLCZ)995670000000391619 |
collection |
bib_alma |
record_format |
marc |
spelling |
Allison, Simon J edt Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action Novel Anti-cancer Agents and Cellular Targets and Their Mechanism MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (206 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ‘Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action’, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges. English Technology: general issues bicssc History of engineering & technology bicssc microtubule acetylation triple-negative breast cancer anti-cancer agent apoptosis K562 8-hydroxydaidzein autophagy BCR-ABL MAPK NF-κB c-myc RNA interference siRNA oncogene gene silencing expression nanosystems Cytochrome P450 CYP1A1 CYP1B1 CYP2W1 breast cancer prodrug bioprecursor duocarmycin phortress AQ4N 5-FU resistance colorectal cancer drug repurposing Genomics of Drug Sensitivity in Cancer Connectivity Map anticancer drug B-lactam steroid alkylators synthetic lethality poly (ADP-ribose) polymerase inhibitors ovarian cancer hybrid steroidal alkylating agents migration invasion glioblastoma CCN1 mesenchymal-amoeboid transition biomarker HepG2 Huh7 isatin sulfonamides angiogenesis cancer hallmarks molecular docking EGFR tyrosine kinase inhibitor photon upconversion triplet-triplet annihilation in vivo imaging PLGA nanoparticles affibody molecule human epidermal growth factor receptor 3 (HER3) BxPC-3 emtansine DM1 albumin binding domain affibody drug conjugate (AffiDC) 3-0365-5221-9 Allison, Simon J oth |
language |
English |
format |
eBook |
author2 |
Allison, Simon J |
author_facet |
Allison, Simon J |
author2_variant |
s j a sj sja |
author2_role |
Sonstige |
title |
Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
spellingShingle |
Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
title_full |
Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
title_fullStr |
Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
title_full_unstemmed |
Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
title_auth |
Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
title_alt |
Novel Anti-cancer Agents and Cellular Targets and Their Mechanism |
title_new |
Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
title_sort |
novel anti-cancer agents and cellular targets and their mechanism(s) of action |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2022 |
physical |
1 electronic resource (206 p.) |
isbn |
3-0365-5222-7 3-0365-5221-9 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT allisonsimonj novelanticanceragentsandcellulartargetsandtheirmechanismsofaction AT allisonsimonj novelanticanceragentsandcellulartargetsandtheirmechanism |
status_str |
n |
ids_txt_mv |
(CKB)5670000000391619 (oapen)https://directory.doabooks.org/handle/20.500.12854/93214 (EXLCZ)995670000000391619 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1787551938360901633 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04224nam-a2201069z--4500</leader><controlfield tag="001">993562964604498</controlfield><controlfield tag="005">20231214133656.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202210s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-0365-5222-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5670000000391619</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/93214</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995670000000391619</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Allison, Simon J</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Novel Anti-cancer Agents and Cellular Targets and Their Mechanism</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (206 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ‘Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action’, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Technology: general issues</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">History of engineering & technology</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microtubule acetylation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">triple-negative breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-cancer agent</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">apoptosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">K562</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">8-hydroxydaidzein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autophagy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BCR-ABL</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MAPK</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NF-κB</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">c-myc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RNA interference</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">siRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncogene</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gene silencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">expression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanosystems</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cytochrome P450</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP1A1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP1B1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP2W1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prodrug</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bioprecursor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">duocarmycin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phortress</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AQ4N</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">5-FU resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">colorectal cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug repurposing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Genomics of Drug Sensitivity in Cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Connectivity Map</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anticancer drug</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">B-lactam steroid alkylators</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">synthetic lethality</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">poly (ADP-ribose) polymerase inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ovarian cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hybrid steroidal alkylating agents</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">migration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">invasion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glioblastoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CCN1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mesenchymal-amoeboid transition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HepG2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Huh7</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">isatin sulfonamides</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">angiogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer hallmarks</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular docking</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EGFR tyrosine kinase inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">photon upconversion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">triplet-triplet annihilation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in vivo imaging</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PLGA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">affibody molecule</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">human epidermal growth factor receptor 3 (HER3)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BxPC-3</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">emtansine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DM1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">albumin binding domain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">affibody drug conjugate (AffiDC)</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-5221-9</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Allison, Simon J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 06:02:20 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-11-05 21:33:14 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5340568990004498&Force_direct=true</subfield><subfield code="Z">5340568990004498</subfield><subfield code="b">Available</subfield><subfield code="8">5340568990004498</subfield></datafield></record></collection> |